Press Release

Statement on U.S. Canada Regulatory Cooperation Council

PhRMA February 8, 2011

Washington, D.C. (Feb. 8, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today upon the creation of the U.S. Canada Regulatory Cooperation Council (RCC):

“PhRMA is pleased that the both the U.S. and Canadian governments realize that greater regulatory harmonization and transparency will promote job growth, innovation and better health and welfare for the citizens of our countries.

“We hope that the establishment of the RCC will lead to tangible changes to regulations that will enable our medicines to get to Canadian patients faster. Scientific knowledge is much more useful when it is shared cooperatively for the benefit of researching better treatments for patients in both the U.S. and Canada.

“We look forward to being a resource for the RCC in identifying areas where greater cooperation can reduce the burdens of regulations on the healthcare systems and help to spur economic growth in our region.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $45.8 billion in 2009 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.

PhRMA Internet Address:
For information on how innovative medicines save lives, visit:
For information on the Partnership for Prescription Assistance, visit:
For more information on public health emergencies, visit
For information on the danger of imported drugs, visit: